| Manufacturer ▼ | Drug Name | Indication | Stage | Status | Route of Administration | Drug Class |
|---|---|---|---|---|---|---|
| Allena Pharmaceuticals Inc. | Reloxaliase (ALLN-177) - (URIROX-2) | Enteric Hyperoxaluria | Phase 3 | Oral | Gastroenterology | |
| Allena Pharmaceuticals Inc. | ALLN-346-202 | Gout in chronic kidney disease (CKD) | Phase 2a | Oral | N/A | |
| Allena Pharmaceuticals Inc. | Reloxaliase ALLN-177 (URIROX-1) | Enteric Hyperoxaluria | Phase 3 | Oral | Gastroenterology | |
| Allogene Therapeutics Inc. | ALLO-501/501A + ALLO-647 - (ALPHA2) | Large B-cell lymphoma | Phase 2 | Data Released | intravenous | Oncology |
| Allogene Therapeutics Inc. | Cemacabtagene ansegedleucel (cema-cel) (ALPHA3) | Large B-Cell Lymphoma (LBCL) | Phase 2 | Ongoing | Intravenous | Oncology |
| Alnylam Pharmaceuticals Inc. | Nucresiran (ALN-TTRsc04) - (TRITON-CM) | ATTR amyloidosis | Phase 3 | Ongoing | Subcutaneous | Genetic Disorder |
| Alnylam Pharmaceuticals Inc. | OXLUMO (lumasiran) - ILLUMINATE-B | Primary Hyperoxaluria Type 1 | Phase 3 | Trial Completed | Subcutaneous | Genetic Disorder |
| Alnylam Pharmaceuticals Inc. | Vutrisiran - (HELIOS-A) | ATTR Amyloidosis | Phase 3 | Data Released | Subcutaneous | Genetic Disorder |